Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder/disease that damages the nerve cells in central nervous system, which is responsible to control the voluntary muscles. Symptoms of ALS are muscle twitching and muscles decreasing in the size. Medications are also prescribed to control ALS symptoms such as pain, stiffness, muscle cramps, excess saliva & phlegm, and pseudo bulbar affect ((involuntary or uncontrolled episodes of crying or laughing and other emotional displays). Drugs also are available to help the individuals with depression, sleep disturbances, pain, and constipation. There are also a number of mechanical tools and devices, such as non-invasive ventilation (NIV) and mechanical ventilation, to help with ALS, such as splints, access extensions and handrails.
Due to the increase in amyotrophic lateral sclerosis, various therapies are also used to treat ALS. These therapies include occupational therapy, physical therapy, respiratory and speech therapy. Advanced technology and a growing aging population are the main drivers of market growth. In addition, growth in disposable income and advancement of research & development activities will further increase overall market demand for ALS throughout the forecast period.
As per analysis, “North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” some of the well-known organizations that are presently operating in the North-America Amyotrophic Lateral Sclerosis (ALS) Treatment market include Corestem, Inc., Sun Pharmaceutical Industries Ltd., Ionis Pharmaceuticals, Inc., Amylyx Pharmaceuticals Inc., BrainStorm Cell Limited, Mitsubishi Tanabe Pharma Corporation, F.Hoffmann-La Roche AG, Biogen Inc., AB Science SA, Otsuka Pharmaceutical Co., Ltd., Biohaven Pharmaceutical Holding Co., Ltd. and among others.
In terms of ALS type, North-America Amyotrophic Lateral Sclerosis (ALS) Treatment market has been bifurcated as sporadic ALS and familial ALS. Sporadic type ALS is most common and can affect anyone whereas the familial or genetic type ALS is rarer. Additionally, in terms of treatment type, market has been bifurcated as medication and stem cell therapy. Medication segment has been further sub-segmented into Nuedexta, Tiglutik (Thickened Riluzole), Radicava (Edaravone), Riluzole (Rilutek) and others. Medications help to relieve symptoms, panic attacks, pain, spasticity, and depression. Nuedexta drug is available as a combination formulation that contains dextromethorphan hydrobromide and quinidine sulfate to treat the effect of pseudobulbs.
The North-America Amyotrophic Lateral Sclerosis (ALS) Treatment market is primarily driven by growth in demand for ALS drugs, followed by rise in prevalence of Amyotrophic Lateral Sclerosis diseases, well- established healthcare infrastructure, growth in healthcare expenditure & technological advancements and favorable reimbursement policies. Additionally, presence of geriatric population is more probable to have these disorders. However, lack of awareness about disease & low treatment availability may impact the market. Moreover, advent of nanotechnology, Internet-of-Things (IoT), machine learning algorithm is a leading opportunity for market.
It is projected that future of the North-America Amyotrophic Lateral Sclerosis (ALS) Treatment market will be optimistic as a result of rise in demand for personalized treatment drugs with growth in geriatric populations during the forecast period.
For More Information, click on the link below:-
North America Amyotrophic Lateral Sclerosis Treatment Market Research Report
Related Report:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
